MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study

BACKGROUND: Chronic visual loss is a disabling feature in patients with multiple sclerosis (MS). It was recently shown that MD1003 (high-dose pharmaceutical-grade biotin or hdPB) may improve disability in patients with progressive MS. OBJECTIVE: The aim of this study was to evaluate whether MD1003 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tourbah, Ayman, Gout, Olivier, Vighetto, Alain, Deburghgraeve, Véronique, Pelletier, Jean, Papeix, Caroline, Lebrun-Frenay, Christine, Labauge, Pierre, Brassat, David, Toosy, Ahmed, Laplaud, David-Axel, Outteryck, Olivier, Moreau, Thibault, Debouverie, Marc, Clavelou, Pierre, Heinzlef, Olivier, De Sèze, Jérôme, Defer, Gilles, Sedel, Frédéric, Arndt, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061426/
https://www.ncbi.nlm.nih.gov/pubmed/29808469
http://dx.doi.org/10.1007/s40263-018-0528-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061426/
https://www.ncbi.nlm.nih.gov/pubmed/29808469
http://dx.doi.org/10.1007/s40263-018-0528-2

Ejemplares similares